Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tat-NR2B9c (NA-1) is a postsynaptic density-95 (PSD-95) inhibitor with neuroprotective and antiepileptic effects.Tat-NR2B9c inhibits PSD-95d2, PSD-95d1, and PSD-95, which prevents the activation of NMDA-induced NADPH oxidase in neurons, thereby blocking the production of superoxide, which reduces ischemic injury in the acute phase after stroke.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $73 | In Stock |
Description | Tat-NR2B9c (NA-1) is a postsynaptic density-95 (PSD-95) inhibitor with neuroprotective and antiepileptic effects.Tat-NR2B9c inhibits PSD-95d2, PSD-95d1, and PSD-95, which prevents the activation of NMDA-induced NADPH oxidase in neurons, thereby blocking the production of superoxide, which reduces ischemic injury in the acute phase after stroke. |
Targets&IC50 | PSD-95d1:670 nM (EC50), PSD-95d2:6.7 nM (EC50) |
In vitro | Similar to the NR2 subunits, Tat-NR2B9c binds to PSD-95d1 and PSD-95d2, and this binding is independent of PDZ interactions, with respective ED50 values of 0.67 μM and 0.067 μM[2]. |
In vivo | Tat-NR2B9c (10 nmol/g, IV) reduced infarct volume by 24.5% and 26.0% following 30 and 60 minutes of tMCAO, respectively, but had no effect on mice at a dose of 3 nM/g[3]. |
Alias | Tat-NR2Bct, NA-1 |
Molecular Weight | 2518.88 |
Formula | C105H188N42O30 |
Cas No. | 500992-11-0 |
Smiles | CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O |
Relative Density. | 1.52 g/cm3 (Predicted) |
Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | H2O: 80 mg/mL (224.57 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.